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INTRODUCTION
The TGF-β superfamily consists of multifunctional
proteins including TGF-βs, activins, and bone mor-
phogenetic proteins (BMPs), which regulate the
growth, differentiation, metabolism, and apoptosis of
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acteristic cysteine-rich follistatin domains. FLRG protein binds to and neutralizes several
transforming growth factor-β (TGF-β) superfamily members, including myostatin (MSTN),
which is a potent negative regulator of skeletal muscle mass. We have previously reported
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to that of FLRG, especially in the valvular apparatus. Biochemical analyses with surface
plasmon resonance biosensor and reporter assays demonstrated that FLRG hardly dis-
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tivities. Our results suggest that FLRG could function as a negative regulator of activin
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various cell types (1-4). The cellular functions and
signaling of these proteins are regulated in diverse
manners, intracellularly and extracellularly. During
investigations of regulatory mechanisms for activin
functions, we have identified a mouse follistatin-like
protein, which was most likely a mouse homologue
of the human follistatin-related gene (FLRG) (5, 6).
Although FLRG was originally cloned at the break-
point of the chromosomal rearrangement in a B cell
chronic lymphocytic leukemia carried at t(11 ; 19)
(q13 ; p13) translocation (7), the physiological func-
tion has not been identified.
Follistatin (FS) is a single chain protein and has
three cysteine-rich FS domains, which are presumed
to be growth factor binding motifs (8, 9). In fact, FS
binds to activins with high affinity, and prevents their
binding to receptors, thereby neutralizing all aspects
of biological activities of activins (4, 10, 11). FS also
functions as a BMP binding protein, although the
affinity for BMPs is much lower than that for activ-
ins (12). We have previously reported that FLRG
protein has domain structures similar to FS and
shows high affinity for activins and BMPs like FS
(5, 13).
Recently, both FS (14, 15) and FLRG (14, 16) pro-
tein have been shown to bind to myostatin (MSTN),
which is another member of the TGF-β superfamily.
MSTN, also known as growth and differentiation fac-
tor 8 (GDF-8), is almost exclusively expressed in de-
veloping and adult skeletal muscle, and functions as
a negative regulator of skeletal muscle mass by con-
trolling myoblast proliferation (17, 18) ; however,
several lines of evidences suggested that MSTN
plays a broader role other than the inhibition of skele-
tal muscle cell growth. Sharma, et al. showed that
MSTN mRNA was detected in fetal and adult heart
tissues, and this gene was upregulated in cardiomyo-
cytes bordering an infarct area (19). Moreover, Cook,
et al. found that MSTN regulated cardiomyocyte
growth through modulation of serine-threonine
kinase AKT signaling by using MSTN-null mice (20,
21).
In this study, we explored the role of FLRG in the
heart during mouse development. We studied the
expression of FLRG in heart by RNA in situ hybridi-
zation and immunohistochemistry. We also analyzed
the expression of FLRG and MSTN genes by using
in vitro P19CL6 cardiomyocyte differentiation system.
Biochemical analyses with reporter assay and bind-
ing assay suggested that FLRG could function as a
negative regulator of activin family members dur-
ing heart development.
MATERIALS AND METHODS
Animals
Pregnant wild-type ICR mice were purchased from
Japan CLEA (Tokyo, Japan). Embryos were retrieved
by Caesarian section from pregnant female mice
anesthetized with diethylether, followed by cervical
dislocation. All animal experiments in this study were
performed in accordance with the guideline princi-
ples of The Institutional Animal Care and Oversight
Committee and were approved by The Committee
for the Care and Use of Animals in The University of
Tokushima Faculty of Medicine.
Hearts and skeletal muscles of hind limbs were dis-
sected from each embryo (E10.5, E12.5 and E14.5),
newborn (P1, P3, P8, and P15) and adult (pregnant
female). The hearts were rinsed with sterile RNase
free phosphate-buffered saline (PBS) containing 10
U/ml heparin, and then used for RNA isolation.
Cell culture and cardiomyocyte differentiation
P19CL6 cells were purchased from RIKEN Gene
Bank (Tsukuba, Japan). Cells were cultured essen-
tially as described previously (22). Briefly, the cells
were grown in a 100-mm tissue culture grade dish un-
der adherent conditions in growth medium (α-MEM)
supplemented with 10% FCS, penicillin (100 U/ml)
and streptomycin (100 μg/ml)). For the induction
of cardiomyocyte differentiation, P19CL6 cells were
plated at a density of 3.7105 in a 60-mm tissue cul-
ture grade dish in growth medium containing 1%
dimethyl sulphoxide (DMSO). The medium was
changed every two days. The first day of DMSO
treatment was designated day 0, and days of differ-
entiation were counted consecutively.
RNA isolation and RT-PCR analysis
For the semi-quantitative analysis of FLRG and
MSTN mRNA expression, total RNA was extracted
from mouse hearts, skeletal muscles, or cultured
P19CL6 cells with TRIzol reagent (Gibco BRL), and
each sample was treated with RNase-free DNase I.
First-strand cDNA was synthesized in a 20 μl reverse
transcriptase (RT) reaction with 3 μg of total RNA us-
ing SuperScript III (Invitrogen) according to the
manufacturer’s protocol. One μl of the RT reaction
was amplified by PCR with 0.25 U of ExTaq DNA po-
lymerase (Takara) in 25 μl of a reaction mixture con-
taining 20 mM Tris-HCl (pH 8.0), 100 mM KCl, 1.5
mMMgCl2, 0.2 mM of each dNTP and 0.5 μM of oli-
gonucleotide primers. The primers used for RT-PCR
analysis are shown in Table 1. β-actin amplification was
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used as an internal control. Full-length cDNA clone
for FLRG in pBluescript vector (Stratagene) and a
HindIII-BamHI fragment of MSTN in pBluescript
vector were used as positive controls (data not shown).
PCR programs were as follows : 94for 5 min, 30
cycles of 94for 1 min, 60for 1 min (for FLRG
cDNA amplification, the annealing temperature was
set at 57) and 72for 1 min. Amplified products
．(20 μl) were resolved by 2% agarose gels, stained
with ethidium bromide, and photographed under UV
light.
RNA in situ hybridization
Mouse embryos were fixed in 4% paraformalde-
hyde and dehydrated before embedding in paraffin.
In situ hybridization was performed on 5-μm-thick par-
affin sections as described (23). The full-length cDNA
clone for FLRG in pBluescript vector, a HindIII-BamHI
fragment of MSTN in pBluescript vector, full-length
cDNA clone for mouse activin A in pGEM-T-Easy
vector (Promega), a NcoI-SpeI fragment of mFS in
pGEM-T-Easy vector, and a BamHI-HindIII fragment
of GDF-11 in pBluescript vector were used to pre-
pare the probe. Digoxigenin-labeled RNA probes
were prepared according to the standard procedure.
In parallel with antisense probes, the corresponding
sense probes were used as negative controls.
Immunohistochemistry
Mouse embryos and hearts dissected from adult
mice were fixed in 4% paraformaldehyde and dehy-
drated before embedding in paraffin wax. Serial sec-
tions were then cut at 8 μm by cryostat, and mounted
on 3-aminopropyltriethoxysilane-coated glass slides.
After deparaffinization and rehydration, sections were
treated with 3% H2O2 in 100% methanol for 30 min
at -20, and then boiled in 10 mM sodium citrate
buffer (pH 6.0) for 5 min. The sections were washed
by TBST (0.1% Tween-20 in Tris-buffered saline)
and then blocked with 1.5% BSA in PBS for 1 hr at
room temperature. The samples were then incubated
with 1 : 100 diluted anti-mouse FLRG monoclonal
antibody or 1 : 100 diluted anti-MSTN monoclonal
antibody (clone JA16 ; Wyeth Research) in block-
ing buffer overnight at 4. Staining without primary
antibodies was used as a negative control. The sec-
tions were washed with three changes of TBST, in-
cubated with horseradish peroxidase-conjugated sec-
ondary antibody for 45 min at room temperature, and
then visualized by ImmunoPure Metal Enhanced
DAB substrate Kit (PIERCE, Rockford, IL). The sec-
tions were also counterstained with hematoxylin.
Purification of human FLRG protein
Bovine activin A was conjugated to affigel-10 col-
umn (BioRad) in 0.5 M NaHCO3 (pH 8.0) buffer at
room temperature for 1 hr and then at 4over-
night. The activin A-conjugated column was equili-
brated with a binding buffer (20 mM Tris-HCl (pH
7.5), 0.15 M NaCl and 0.03% CHAPS) before use.
CHO cells stably expressing human FLRG were
grown in α-MEM supplemented with 10% FCS until
confluency, and then conditioned with serum-free
EC-CELL301 medium. The conditioned medium was
first fractionated by ammonium sulfate precipitation
(30-80%), and then passed through an activin A-
conjugated column at a flow rate of 0.2 ml/min. Col-
umns were washed with binding buffer, and then
eluted with elution buffer (20 mM Tris-HCl (pH 7.5),
1.0 M NaCl, 0.03% CHAPS containing 1 M Guanidine-
HCl). Eluted proteins were concentrated by ultrafil-
tration, and the buffer was changed to PBS contain-
ing 0.03% CHAPS. Samples were resolved by 12.5%
SDS-PAGE and blotted onto a PVDF membrane.
Table 1 Oligonucleotide primers used for RT-PCR in this study
Gene GenBankAccession No. Primer sequence
FLRG AB024429 F : 5’-ACTCTGTGGCAACAACAACG-3’ (621-640)R : 5’-TTCTCTTCCTCCTCTGCTGG-3’ (742-761)
MSTN NM_010834 F : 5’-GCACTGGTATTTGGCAGAGTA-3’ (702-722)R : 5’-CACACTCTCCTGAGCAGTAAT-3’ (1026-1046)
Nkx 2.5 X75415 F : 5’-TCTCCGATCCATCCCACTTTATTG-3’ (1368-1391)R : 5’-TTGCGTTACGCACTCACTTTAATG-3’ (1566-1589)
GATA4 NM_008092 F : 5’-AGCAGGACTCTTGGAACAGC-3’ (1872-1891)R : 5’-CAGGCAGGTGGAGAATAAGG-3’ (2214-2233)
β-actin NM_007393 F : 5’-CCTGGAGAAGAGCTATGAGCTGC-3’ (785-807)R : 5’-TGCTGATCCACATCTGCTGGAAG-3’ (1133-1155)
The sequence of forward (F) and reverse (R) strand primers are shown together with GenBank accession numbers relating to the
DNA sequences from which they were obtained.
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FLRG protein was detected with anti-human FLRG
antibody followed by enhanced chemiluminescence
(ECL) reaction.
Surface plasmon resonance (SPR) biosensor analysis
All measurements were performed using a
BIACORE X system (Biacore AB). For immobilized
samples, proteins were dissolved in 20 mM sodium
acetate (pH 4.5) at a concentration of 10 μg/ml and
immobilized on sensor chip CM5 at a flow rate of
5 ml/min at 25. The immobilized ligands were re-
generated after each cycle using a 40 ml injection of
10 mM HEPES (pH 7.4) / 2 M guanidine-HCl. The
kinetic parameters, association rate constant (kon)
and dissociation rate constant (koff) were determined
using BIA evaluation software version 3.0 (Biacore
AB).
FLRG protein was purified as described above. Bo-
vine activin A and human FS-288 were purified as
described previously (24). Human MSTN, GDF-11
and BMP proteins were either from R&D systems
or Wyeth Research.
Luciferase assays
HEK293 cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM, Sigma), supplemented
with 10% FCS. Cells plated at a density of 4104 in
a 24-well dishes were transfected with 500 ng of
CAGA-luc reporter DNA, and 200 ng of the cytomega-
lovirus promoter-βgal (CMV-βgal) DNA by the cal-
cium phosphate precipitation method (25). Twenty-
four hours after transfection, the cells were stimu-
lated with activin A (20 ng/ml), TGF-β1 (15 ng/ml),
MSTN (20 ng/ml) or GDF-11 (20 ng/ml) in media
containing 1% FCS for 24 hr. In order to study
whether FS or FLRG has inhibitory effects on ac-
tivin A, TGF-β1, MSTN or GDF-11, FS or FLRG pro-
teins were simultaneously added to these stimulants.
Luciferase activity was normalized to β -galactosidase
activity as described previously (26).
RESULTS
Expression of FLRG and MSTN mRNAs in heart
and limbs during mouse development
First, we analyzed the expression of FLRG dur-
ing cardiac muscle development in mouse. For this
purpose, we purified hearts mRNAs from mouse em-
bryos, newborn littermates and adult mice, and per-
formed RT-PCR analysis with the set of primers
listed in Table 1. In adult mice, FLRG mRNA was
abundantly expressed in the heart (Fig. 1A), as we
reported previously (5). During development, FLRG
mRNA was continuously expressed in the heart from
the early embryonic stage (E10.5) to adult (Fig. 1A,
upper panel). When we analyzed the expression of
MSTN, one of the binding partners for FLRG, MSTN
mRNA was also expressed in the heart during the
early embryonic stage (E10.5-14.5). The expression,
however, dropped after birth, and then later gradu-
ally increased but did not reach to the expression
level at E10.5 (Fig. 1A, middle panel).
When the expressions of these genes were ana-
lyzed in skeletal muscle obtained from the hind limbs
of the same animals, we found that skeletal muscle
constantly expressed MSTN mRNA during devel-
opment (Fig. 1B, middle panel). In contrast to the
heart, however, a very limited amount of FLRG
mRNA was expressed in skeletal muscle during em-
bryogenesis. The expression of FLRG mRNA was
transiently increased in embryos at E14.5, and then
decreased after birth (Fig. 1B, upper panel). These
results raised the possibility that FLRG may regu-
late the development and maintenance of heart tis-
sue, similarly as MSTN regulates the growth and dif-
ferentiation of skeletal muscles.
Expression of FLRG and MSTN mRNAs in differ-
entiating P19CL6 cells
To verify the characteristic expression of FLRG
and MSTN mRNAs during heart development, we
took advantage of the P19CL6 in vitro cardiomyocyte
differentiation system. The P19CL6 cell line is a sub-
A
B
Fig. 1 Expression profiles of FLRG and MSTN mRNAs in heart
and limb during mouse development.
Mouse heart ventricles and skeletal muscle of hind limbs were
collected from embryos (E10.5, E12.5, and E14.5), newborns
(P1, P3, P8 and P15) and adults (pregnant female). Total RNAs
were isolated from each sample and RT-PCR was performed to
detect FLRG and MSTN mRNAs expression. β-actin was used
as the internal control.
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line of P19 embryonic carcinoma stem cells. This
cell line shows efficient differentiation into beating
cardiac myocytes after induction with DMSO (22).
When we cultured P19CL6 in the presence of 1%
DMSO, the first contraction was observed at some
part of the restricted area of the sheet on day 12. On
day 14, almost all parts of the sheet beat synchro-
nously. Under these conditions, the expression of
FLRG, MSTN, and early cardiac-specific regulatory
genes, nkx2.5 and gata4 , were analyzed by RT-PCR
in four stages (day 4, 8, 12, 16). As previously re-
ported (27), cells expressed gata4 as early as 4 days
after DMSO treatment, and then nkx2.5 was detected
at day 8 (Fig. 2), suggesting that P19CL6 cells spe-
cifically differentiated to cardiomyocytes. FLRG
mRNA was detected at day 4, and continued to be
expressed after synchronous beating occurred. On
the other hand, the expression of MSTN mRNA was
observed after day 12, concurrently with spontane-
ous beating. In control P19CL6 cells, we failed to
detect either FLRG mRNA expression by RT-PCR,
or FLRG protein by Western blotting, although we
detected the expression of FLRG protein in cardio-
genic P19CL6 cells on day 6 by immunofluorescence
(data not shown). These results further strengthen
the hypothesis that MSTN and the binding protein,
FLRG, are involved in the cardiomyogenesis of this
cell line.
RNA in situ hybridization of FLRG and MSTN
mRNAs in the mouse embryonic heart
In order to analyze the localization of FLRG and
MSTN mRNAs in the mouse embryonic heart, in situ
hybridization was performed with E14.5 mouse em-
bryos, which express both genes (Fig. 1A).
FLRG mRNA was clearly detected in the smooth
muscle of the aorta (Fig. 3G, H, I) and pulmonary
Fig. 2 Expression of FLRG and MSTN mRNAs during in vitro
cardiomyocyte differentiation in P19CL6 cells.
Cardiomyocyte differentiation was induced in P19CL6 cells by
adding 1% DMSO to the growth medium. Twelve days after DMSO
treatment, the first contraction was observed in some part of the
restricted area of cells. Temporal changes of the expression of
FLRG, MSTN, Nkx2.5, and GATA4. mRNAs were analyzed by
RT-PCR. β-actin was used as the internal control.
Fig. 3 Localization of FLRG, MSTN, activin, and FS mRNAs in mouse embryonic heart.
Serial sections of E14.5 mouse heart were analyzed by RNA in situ hybridization. Localization of FLRG (G-L), MSTN (M-R), activin
(S-X), and FS (Y, Z) mRNAs is shown. Sense signals of FLRG (A-F) were shown as the controls. ao indicates aorta ; as, atrial sep-
tum ; av, aortic valve ; la, left atrium ; lv, left ventricle ; mv, mitral valve ; pa, pulmonary artery ; pv, pulmonary valve ; tv, tricuspid
valve ; ra, right atrium ; rv, right ventricle ; vs, ventricular septum.
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artery (Fig. 3G). The mRNA was also detected in
valve leaflets of the mitral valve (Fig. 3J, K, white
arrow) and tricuspid valve (Fig. 3L, white arrow).
Besides these tissues, FLRG mRNA was widely ex-
pressed in cardiac muscles of the ventricle. Since
FLRG protein binds to MSTN and neutralizes the
functions, we expected that these two mRNAs either
colocalized or were adjacent to each other. The ex-
pression of MSTN mRNA was, however, quite dis-
tinct and was detected in the valve leaflets of the
pulmonary valve (Fig. 3M, N, red arrow) and aor-
tic valve (Fig. 3N, O, blue arrow). FLRG mRNA was
not detected in these tissues (Fig. 3G, I, black ar-
rows). MSTN mRNA was also detected at the top
of the ventricular septum (Fig. 3Q, yellow arrow)
and in the atrial septum (Fig. 3R, brown arrow).
According to the previous report, activin and FS
mRNAs were also expressed in the E10.5-12.5 mouse
embryonic heart (28). Thus, we further analyzed the
expression of these genes with the same samples.
In our study with E14.5 mouse embryos, activin
mRNA was strongly expressed in the smooth mus-
cle of the aorta (Fig. 3S, T, U) and pulmonary ar-
tery (Fig. 3S), and the valve leaflets of the mitral
valve (Fig. 3V, W, white arrow) and tricuspid valve
(Fig. 3W, X, white arrow). On the other hand, FS
mRNA was detected at the atrial septum, as de-
scribed previously (28), and was also detected at
mitral and tricuspid valves (Fig. 3Y and Z). These
results indicated that expression profiles of FLRG
and activin mRNAs resembled each other, and that
the expression of MSTN mRNA was complemen-
tary to that of FLRG.
Immunohistochemical analysis of FLRG protein in
fetal and adult mouse hearts
We further analyzed the tissue distribution of
FLRG protein in the fetal and adult mouse heart by
immunohistochemistry with a monoclonal anti-mouse
FLRG antibody (5, 29). In E13.5 mouse embryos,
which also express both FLRG and MSTN mRNA,
FLRG protein was detected clearly in the heart mus-
cle of the atrium with anti-FLRG antibody, and rather
diffusely in the ventricle (Fig. 4A and B). Other tis-
sues, such as the lung (Fig. 4B) and metanephros
(Fig. 4C), were also stained but rather weakly. In
adult mouse hearts, similar immunoreactivity was
observed as in embryonic hearts, although the ex-
pression of FLRG in the ventricle was as strong as
in the atrium (Fig. 4E and F). As in our previous re-
port (29), FLRG was widely detected in adult heart
muscles but not in the nuclei of cardiomyocytes
(data not shown). On the other hand, no signal was
detected in the vascular smooth muscle of the aorta
(Fig. 4D, arrow) and pulmonary artery (Fig. 4D),
or in the pulmonary valve leaflets (Fig. 4D, black
arrowhead) of adult mice. In the mitral valve, how-
ever, FLRG staining was detected in the upper layer
of the valve leaflets (Fig. 4F, asterisks).
In order to confirm the expression of FLRG and
MSTN protein in valvular apparatus in the mouse em-
bryonic heart, we further analyzed the localization
of these proteins by immunohistochemistry (Fig. 5).
To do this, we used the JA16 monoclonal antibody
against MSTN, which was previously reported (14,
16, 30). In the E12.5 embryonic heart, both FLRG
and MSTN proteins were clearly detected in cardi-
omyocytes of the atrium and ventricles (Fig. 5A and
D), and their respective immunoreactivity resem-
bled each other. In the region of the outflow tract
cushion, however, the subcellular localization of
FLRG protein was different from that of MSTN. FLRG
protein was mainly detected in the nucleus (Fig. 5B
and C, yellow-dotted area) as previously reported
with human granulosa cells and several other cell
lines (13, 31). In contrast, MSTN protein was found
in the cytosol of the outflow tract cushion cells (Fig.
5E and F, yellow-dotted area). The role of FLRG
localized in the nuclei of the cells in this tissue re-
mains to be determined. Interestingly, conspicuous
FLRG signals were also detected at the top of the
outflow cushion, where the pulmonary valve (Fig. 5B,
pink arrowheads) and aortic valve (Fig. 5C, green
arrowheads) would be formed, and MSTN message
was also detected at the surface of these valve leaf-
lets (Fig. 5E, pink arrows and Fig. 5F, green arrows).
These findings suggest that FLRG and MSTN could
regulate not only cardiomyogenesis but also valvulo-
genesis during cardiac development.
In order to test the involvement of other activin
and FS members for valve formation, we carefully
compared these expressions by in situ hybridization
with the E14.5 embryonic heart (Fig. 6). The ex-
pression patterns of activin and FLRG were very
similar (Fig. 6A and E), but not identical (Fig. 6G).
Interestingly, FLRG mRNA was localized rather com-
plementary to MSTN mRNA around the aortic valve
(Fig.6D, E, G). Similarly, the expression of GDF-11
mRNA was complementary to that of activin (Fig.6
A and B). This mRNA expression profiling suggests
that activin family members including MSTN and
two regulatory factors, FLRG and FS, are coopera-
tively involved in valvulogenesis during heart devel-
opment.
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A B C
D E F
Fig. 4 Immunohistochemical analysis of FLRG protein in fetal and adult mouse heart.
A-C : Sagittal section of E13.5 mouse embryo (A) and enlargement of boxed area in A (B), dotted area in A (C). D, E : Coronal
sections of mouse adult heart. F : Enlargement of mitral valve of adult mouse (boxed area in E). RA indicates right atrium ; LA, left
atrium ; RV, right ventricle ; LV, left ventricle ; Ao, aorta ; PA, pulmonary artery ; OFT, outflow tract ; MV, mitral valve ; a, atrium ; v,
ventricle ; lu, lung ; lv, liver ; ma, metanephros.
A B C
D E F
Fig. 5 Localization of FLRG and MSTN proteins in valvular apparatus of E12.5 embryonic heart.
Immunohistochemical analysis of FLRG (A-C) and MSTN (D-F) proteins in embryonic heart. A, D : Coronal sections of E12.5
mouse embryonic heart. B, E : Enlargement of outflow tract of right ventricle. C, F : Enlargement of aortic valve. RA indicates right
atrium ; LA, left atrium ; RV, right ventricle ; LV, left ventricle ; Ao, aorta ; PA, pulmonary artery ; OFT, outflow tract ; OFT-C, outflow tract
cushion.
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Inhibitory effect of FLRG protein on MSTN and
other activin family member signaling
To elucidate the roles of FLRG, we compared the
affinity of FLRG for MSTN and other TGF-β super-
family member proteins. First, we prepared recom-
binant FLRG protein by transient transfection of Chi-
nese hamster ovary (CHO) cells with a human FLRG
(hFLRG) expression plasmid followed by partial pu-
rification by passing the conditioned medium through
an activin A-conjugated column. Purified hFLRG pro-
tein was resolved by SDS-PAGE and immunoblot-
ted with the monoclonal anti-human FLRG antibody.
As shown in Fig. 7, recombinant hFLRG protein with
an apparent molecular mass of 37 kDa was gener-
ated. Next, we performed surface plasmon resonance
(SPR) biosensor analysis using a BIACORE system.
We also used human FS-288, which is the splicing
isoform of FS that has stronger inhibitory activity
against activin than the other isoform, FS-315 (32,
33). FLRG or FS-288 was immobilized on a BIACORE
sensor chip, and then MSTN protein and other TGF-β
superfamily members were injected to flow over the
sensor chip as analytes. As shown in Table 2, the
affinity (Kd) of MSTN for FLRG was comparable
with that for FS-288. Activin showed around 10 times
higher affinity than MSTN for FLRG or FS-288. In
contrast, BMP2 showed 10 times lower affinity for
these proteins. Interestingly, the dissociation con-
stant (koff) of MSTN indicated that MSTN slowly
dissociates from FLRG or FS-288 than other TGF-β
superfamily members. These results suggested that
MSTN did not efficiently bind to FLRG or FS as ac-
tivin did due to its low association constant (kon),
A D
Fig. 6 mRNA expression of activin and
FS members around aorta and aortic valve
leaflets.
RNA in situ hybridization analysis of se-
rial sections around aorta of E14.5 mouse
heart. Localization of activin (A), GDF-
11 (B), FS (C), MSTN (D), and FLRG
(E) mRNAs are shown. Sense signal of
FLRG (F) is shown as the control. Local-
ization of each mRNA is respectively in-
dicated in the illustration next to each pho-
tograph. These expression patterns were
merged as shown in G.
B E
C F G
Fig. 7 Recombinant human FLRG protein purified through an
immobilized activin column.
Human FLRG protein, secreted by CHO cells, was partially pu-
rified by passing through the activin column. The sample was re-
solved by 12.5% SDS-PAGE and blotted with anti-human FLRG
antibody. The signal was detected by enhanced chemilumines-
cence. Molecular mass markers are indicated on the left.
Table 2 Kinetic rate constants of FLRG/FS-288 and Activin A, BMP-2, MSTN, GDF-11 binding
Analyte Ligand kon koff Kd
MSTN FLRG 5.73104 9.4010-4 1.6410-8
Activin A FLRG 1.68106 1.2410-3 7.3610-10
BMP-2 FLRG 3.26105 3.9510-2 1.2110-7
GDF-11 FLRG 9.14104 4.1010-3 4.4910-8
MSTN FS-288 5.29104 6.5110-4 1.2310-8
Activin A FS-288 8.31105 1.4310-3 1.7210-9
BMP-2 FS-288 4.48105 6.9010-2 1.3610-7
GDF-11 FS-288 2.61105 1.2910-3 4.9510-9
General curve fitting was performed for 12.5-200 nM of analyte.
A 1 : 1 binding with mass transfer was used as a model.
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whereas once MSTN bound to FLRG or FS, these
complexes could be stable.
Next, we examined the inhibitory effect of
hFLRG and hFS on activin A- or TGF-β1-induced
signaling with human embryonic kidney (HEK293)
cells transfected with a Smad-specific reporter plas-
mid, 12CAGA-luc. Both hFLRG and hFS decreased
the activin A-induced 12CAGA-luc transcriptional
activities in a dose-dependent manner, whereas these
proteins failed to inhibit the TGF-β1-induced signal
(Fig. 8A). We also observed that hFLRG has a
stronger inhibitory effect than hFS on activin sig-
naling. Similar inhibitory effects of FLRG either on
MSTN- or GDF-11-induced signaling were observed
A
B C
Fig. 8 Inhibition of ligand-dependent transcription by FLRG or FS.
A, Inhibition of activin A or TGF-β1 signaling by hFLRG or hFS protein in HEK293 cells. HEK293 cells were transfected with CAGA-
lux and CMV-βgal, and cultured with activin A (20 ng/ml) or TGF-β1 (15 ng/ml) with or without different concentrations of hFLRG
or hFS proteins for 24 h. The luciferase activity of each cell lysate was measured and normalized to β -galactosidase activity. The
meanSE of triplicate determination is shown.
B, C, Inhibition of MSTN or GDF-11 signaling by hFLRG or hFS protein in HEK293 cells. HEK293 cells were transfected with CAGA-
・lux and CMV-βgal, and cultured with MSTN (20 ng/ml) or GDF-11 (20 ng/ml) as described in A.
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in a dose-dependent manner (Fig. 8B and C). These
results suggested that FLRG expressed in the heart
could negatively regulate the activin family mem-
bers including MSTN during heart development.
DISCUSSION
In this study, we demonstrated that FLRG mRNA
was constantly expressed in the heart, whereas it was
expressed in skeletal muscles at a very low level, dur-
ing various stages of mouse development. In con-
trast, MSTN was stably expressed in skeletal mus-
cles but not in the heart during development (Fig. 1).
The high expression of FLRG mRNA in cardiac tis-
sue was also confirmed by in vitro cardiomyocyte
differentiation using P19CL6 cells (Fig. 2). We have
previously shown that human FLRG mRNA was
abundantly expressed in the heart, and was detected
in skeletal muscle at a low level (5). Further detail
expression analyses of these genes during embryo-
genesis encouraged us to hypothesize that FLRG
and MSTN have functional roles during cardiomyo-
genesis.
Various members of the TGF-β superfamily, in-
cluding activins and BMPs, are involved in cardiac
development. In particular, activin has been shown
to regulate cardiac myogenesis in the early stage of
chick embryogenesis (34, 35). MSTN is well known
as a potent negative regulator for skeletal muscles ;
therefore, MSTN has been considered to function
specifically in skeletal muscles. However, other
groups have shown that MSTN mRNA is also ex-
pressed in the heart (19). Moreover, a recent study
revealed that the expression of MSTN increases in
hypertrophied cardiomyocytes (20, 36). This raises
a possibility that MSTN may function as a negative
feedback regulator to counteract these pathological
phenomenon. These observations further support
our hypothesis that MSTN also plays some roles dur-
ing heart development.
During chick skeletal muscle development, the
activity of MSTN is regulated by a neutralizing fac-
tor, FS. FS, which increases muscle mass by inhib-
iting the MSTN-dependent growth arrest of skele-
tal muscles (37). Since another neutralizing factor,
FLRG, is also expressed and shows a distinct ex-
pression during heart development, both FLRG and
FS may be cooperatively involved in the regulation
of cardiac tissues.
The members of the TGF-β superfamily are ca-
pable of inducing the transformation of endocardial
cells into mesenchymal cells, which initiates atriov-
entricular (AV) cushion formation (38-40). Activin
βA has been reported to be expressed in mesenchy-
mal cells of the AV cushion, and to induce endothelial-
to-mesenchymal transformation (EMT) (41). When
we analyzed the expression of activin mRNA in E14.5
mouse embryos by in situ hybridization, it was mainly
detected in smooth muscle of the aorta and pulmo-
nary artery, some valve leaflets, and cardiac muscles
in the ventricle. Intriguingly, the localization of ac-
tivin mRNA in great arteries or valvular structures
was quite similar to that of FLRG mRNA, but did not
completely overlap with that of MSTN mRNA (Fig.
6). The localization of MSTN mRNA was rather
complementary to that of FLRG mRNA (Fig. 6D and
E). Amthor, et al. also described similar complemen-
tary expressions of MSTN and FS mRNAs during
wing and interlimb somite development in chick em-
bryos. They demonstrated that FS prevented the in-
hibiting effect of MSTN on skeletal muscle develop-
ment both in vivo and in vitro (37). Combining these
findings, we speculate that during heart develop-
ment, MSTN could be involved in aortic valve or
pulmonary valve formation in cooperation with the
negative regulator in the heart, FLRG. We have also
shown that GDF-11, a close family member of MSTN,
is expressed in similar tissues as MSTN (Fig. 6).
No cardiac anomaly of MSTN-knockout mice could
be due to compensation of MSTN absence by GDF-11
(17).
By using the surface plasmon resonance biosen-
sor analysis, we have shown that the dissociation
constant of MSTN against FLRG or FS-288 was low
compared to other TGB-β family members. This sug-
gests that MSTN hardly dissociate from FLRG or
FS-288, thus MSTN can form a stable complex with
these molecules. Intriguingly, Hill, et al. previously
reported that the MSTN complex immunopurified
from serum with anti-MSTN monoclonal antibody
contained FLRG but not FS, indicating that MSTN
forms a complex with FLRG but not FS in vivo (16).
FS-288 has much higher affinity against activin than
the major form, FS-315 (32, 33). Moreover, FS-288
also binds to heparan sulfate proteoglycans on the
cell surface, and therefore functions to sequester
activin family members more tightly in the extra-
cellular matrix (32). Based on this information, our
data suggest that MSTN is not only neutralized by
forming a stable complex with FLRG in serum but
also negatively regulated by FS-288 expressed locally
during heart development.
Recently, regenerative medicine has attracted
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many researchers and is leading to new ways to
repair and regenerate cardiac disorders. Therapy by
transplantation of bone marrow stem cells or tissue-
derived stem cells into damaged cardiac tissue after
myocardial infarction has been investigated (42) ;
however, for children with severe congenital heart
anomalies or lethal heart diseases like dilated car-
diomyopathy, invasive therapies such as surgical
operation or heart transplantation are still required.
Further understanding of the regulatory factors dur-
ing cardiac development is needed to enable less-
invasive therapy for these patients.
In summary, our results suggest that MSTN, and
its negative regulator, FLRG, could be involved in
cardiac muscle development and valvulogenesis in
cooperation with activin and FS.
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